🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

34 results for “atezolizumab” Clear

  1. A Phase III, Randomized, Double-Blind Study of Tiragolumab Plus Atezolizumab Compared with Placebo Plus Atezolizumab in Participants with Completely Resected Stage IIB, IIIA, or Select IIIB, PD-L1 Positive, Non-Small Cell Lung Cancer who have received Adjuvant Platinum-Based Chemotherapy

    Roche Registration Limited

    Non-Small Cell Lung Cancer

    phase 3 other active

    1 trial

  2. AVELUMAB, DOSTARLIMAB, ATEZOLIZUMAB, AVELUMAB, CEMIPLIMAB, DOSTARLIMAB, NIVOLUMAB, PEMBROLIZUMAB, NIVOLUMAB, DURVALUMAB, CEMIPLIMAB, ATEZOLIZUMAB, PEMBROLIZUMAB, DURVALUMAB

    Cancer Prevention Pharma (Ireland) Limited

    Only patients with oncologic locally advanced or metastatic tumour (lung cancer, renal cell cancer (except IMDC favorable-risk treated Tyrosine Kinase Inhibitor [TKI] / immunotherapy [IO] combination), head and neck cancer, urothelial carcinoma, triple negative breast cancer, Merkel cancer, melanoma, hepatocellular carcinoma, colorectal carcinoma with microsatellite instability [MSI], esophageal squamous cell carcinoma, endometrial carcinoma, or cervical cancer, gastric/gastro-esophageal junction/esophageal adenocarcinoma, basal cell carcinoma or squamous skin carcinoma) in partial or complete response (except for melanoma, only patients in partial response) after 6 months of standard IO treatment (monotherapy or previously in combination with other immunotherapy (ipilimumab) or chemotherapy or continuous combination with pemetrexed or bevacizumab or TKI).

    phase 3 small molecule active

    1 trial

  3. Atezolizumab

    Jazz Pharmaceuticals Ireland Limited

    Small-Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  4. ETOPOSIDE, ATEZOLIZUMAB, PF-08634404, CARBOPLATIN

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Extensive-Stage Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  5. ETOPOSIDE, Atigotatug + Nivolumab FDC, CARBOPLATIN, ATEZOLIZUMAB

    Bristol-Myers Squibb / Pfizer EEIG

    Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

    phase 3 small molecule active

    1 trial

  6. INFLIXIMAB, Rilvegostomig, MYCOPHENOLATE MOFETIL, IMJUDO 20 mg/ml concentrate for solution for infusion., IMJUDO 20 mg/ml concentrate for solution for infusion., ATEZOLIZUMAB , BEVACIZUMAB

    AstraZeneca AB

    Advanced Hepatocellular Carcinoma

    phase 3 small molecule active

    1 trial

  7. Livmoniplimab, ATEZOLIZUMAB, TREMELIMUMAB, BEVACIZUMAB, Budigalimab, IMFINZI 50 mg/mL concentrate for solution for infusion.

    AbbVie Deutschland GmbH & Co. KG

    Metastatic Hepatocellular Carcinoma (HCC)

    phase 3 small molecule active

    1 trial

  8. NIVOLUMAB, GEMCITABINE, TEPMETKO 225 mg film-coated tablets, PACLITAXEL, DOCETAXEL, ATEZOLIZUMAB, BEVACIZUMAB, PEMBROLIZUMAB, VINORELBINE, PEMETREXED

    CERO THERAPEUTICS HOLDINGS, INC.

    Advanced MET exon 14 Mutated Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  9. A Phase II, Single-Arm, Open-Label Study Evaluating the Safety and Pharmacokinetics of the Intravenous Fixed‑Dose Combination (IV FDC) of Tiragolumab and Atezolizumab in Participants with Locally Advanced, Recurrent or Metastatic Solid Tumors

    Roche Registration Limited

    Solid Tumors

    phase 2 other active

    1 trial

  10. ATEZOLIZUMAB

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Patients with metastatic tumours (colorectal, non-small cell lung, renal and sarcoma)

    phase 2 small molecule active

    1 trial

  11. ATEZOLIZUMAB, COBIMETINIB, VEMURAFENIB

    Fondazione Telethon ETS

    high-risk, surgically resectable BRAF mutated and wild-type Melanoma

    phase 2 small molecule active

    1 trial

  12. Abraxane 5 mg/ml powder for dispersion for infusion., Gemcitabin-GRY 1000 mg Pulver zur Herstellung einer Infusionslösung, RoActemra 20 mg/mL concentrate for solution for infusion, Gemcitabin AqVida 38 mg/ml Pulver zur Herstellung einer Infusionslösung, Gemcitabin Kabi 38 mg/ml Pulver zur Herstellung einer Infusionslösung, Avastin 25 mg/ml concentrate for solution for infusion., ATEZOLIZUMAB, Tiragolumab

    Roche Registration Limited

    Pancreatic ductal adenocarcinoma (PDAC)

    phase 2 small molecule active

    1 trial

  13. An Open-Label, Multi-Center, Phase Ib/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin (Plus A Single Pretreatment Dose of Obinutuzumab) in Adult Patients with Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma

    Roche Registration Limited

    Relapsed/refractory (r/r) B-cell Non-Hodgkin’s Lymphoma (NHL)

    phase 2 other active

    1 trial

  14. Association atezolizumab + BDB001 + RT

    Eikon Therapeutics

    Solid Tumor, Adult

    phase 2 small molecule active

    1 trial

  15. Atezolizumab

    Arcus Biosciences

    Prostate Adenocarcinoma

    phase 2 small molecule active

    1 trial

  16. Atezolizumab

    Beone Medicines Ireland Limited

    Advanced Liver Cancers

    phase 2 small molecule active

    1 trial

  17. Atezolizumab

    United Therapeutics Europe Ltd

    Locally Advanced Hepatocellular Carcinoma

    phase 2 mab active

    1 trial

  18. Atezolizumab

    United Therapeutics Europe Ltd

    Metastatic Colorectal Carcinoma

    phase 2 small molecule completed

    1 trial

  19. Atezolizumab

    HALOZYME THERAPEUTICS, INC.

    Pancreatic Ductal Adenocarcinoma

    phase 2 small molecule terminated

    1 trial

  20. Atezolizumab

    Syndax Pharmaceuticals Inc

    Metastatic Cancer

    phase 2 small molecule terminated

    1 trial

  21. Atezolizumab

    China SXT Pharmaceuticals

    Small-cell Lung Cancer

    phase 2 small molecule active

    1 trial

  22. Atezolizumab

    Oncotelic Therapeutics

    Metastatic Lung Non-Small Cell Carcinoma

    phase 2 mab terminated

    1 trial

  23. BEVACIZUMAB, ATEZOLIZUMAB

    Pari Pharma GmbH

    liver transplanted patients with advanced hepatocellular carcinoma

    phase 2 small molecule active

    1 trial

  24. BNT327 50 mg ml, BNT327 20 mg ml, IPILIMUMAB, ATEZOLIZUMAB, ATEZOLIZUMAB, BEVACIZUMAB, Ipilimumab

    Bristol-Myers Squibb / Pfizer EEIG

    Advanced or unresectable Hepatocellular Carcinoma (HCC)

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources